Novavax Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Novavax Inc 's ROA in the second quarter of 2026?
Novavax Inc recorded a cumulative net loss of $-248 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -22.97%.

However, within the Healthcare sector 375 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 132 to 3093.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-27.62 %	-18.65 %	-16.15 %	-25.89 %	-19.53 %
Y / Y Net Income Change	-	-	-	-	-34.41 %
Net Income (TTM) in million	-248	-88	440	342	423
Return On Assets (TTM)	-22.97 %	-7.51 %	35.8 %	26.57 %	30.5 %
NVAX's Total Ranking	# 3093	# 132	# 172	# 145	# 136
Total Assets (TTM) in million	960	1,043	1,166	1,146	1,326
Seq. Total Assets Change	-8 %	-10.51 %	1.72 %	-13.56 %	3.39 %
Seq. Net Income Change	-	-	-	-	-79.46 %

NVAX's 5 Years Annual ROA >> Back to NVAX Management Effectiveness >> Compare NVAX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 38
Sector	# 376
Overall	# 3479

Return On Assets Statistics
High	Average	Low
35.32 %	-39.35 %	-86.4 %
(Dec 31 2025)		(Dec 31 2020)

Financial Statements
Novavax Inc 's Assets	$ 960 million	NVAX's Balance sheet
Novavax Inc 's Income	$ -53 million	Quarterly NVAX's Income Statement
NVAX's Income by Division		See NVAX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-16.15 %	-13.31 %	-28.67 %	-12.35 %	53.72 %
Total Assets in million	1,166	1,390	1,604	2,248	2,565
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	440	-187	-545	-658	-1,744
Annual Return On Assets	37.77 %	-13.49 %	-33.99 %	-29.26 %	-67.98 %

NVAX's 5 Years Annual ROA >> Back to NVAX Management Effectiveness >> Compare NVAX ROA to its Competitors

Comment on NVAX's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 37.77 % compared to prior year, due to annual net income growth of % to $440.30 million, and due to decline of value in Novavax Inc 's assets by -16.15 % to $1,165.64 million, compared to $1,165.64 a year before.

More Return On Assets Ratios
NVAX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NVAX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NVAX's Competitors
Subscribers only: Roa for Novavax Inc 's Suppliers
Subscribers only: Return On Assets for NVAX's Customers

You may also want to know
NVAX's Roi	NVAX's Inventory Turnover Ratio	NVAX's Growth Rates	NVAX's Dividend Comparisons
	NVAX's Profitability Ratios	NVAX's Asset Turnover Ratio	NVAX's Dividend Growth
NVAX's Roe	NVAX's Valuation Ratios	NVAX's Financial Strength Ratios	NVAX's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T06:50:52+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.